Sonoma Pharmaceuticals and MicroSafe Group, Dubai Sonoma Pharmaceuticals (SNOA) develops stabilized hypochlorous acid (HOCl) products for a wide range of applications including: wound care, eye care and dermatological conditions. Together with MicroSafe Group, Dubai, announced the receipt of approval from Australia for Nanocyn® Disinfectant & Sanitizer, manufactured by Sonoma using its . . . This content is for paid subscribers. Please click here to subscribe or …
Nektar Therapeutics Nektar Therapeutics (NKTR) announced the publication of Phase 1 clinical data for its immuno-oncology candidate, bempegaldesleukin (BEMPEG: NKTR-214) + nivolumab, in Cancer Discovery - a journal of the American Association for Cancer Research. Previously published Phase 1 data in Cancer Discovery informed that BEMPEG administered as monotherapy . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Moderna Inc: A Public Offering Moderna (MRNA) announced the pricing of an underwritten public offering of 17,600,000 shares of common stock at a public offering price of $76.00 per share, before underwriting discounts and commissions. Moderna has also granted the underwriters a 30-day option to purchase up to an additional 2,640,000 shares of . . . This content is for paid subscribers. Please click here to subscribe or …
Moderna Coronavirus Vaccine Cleared for Phase 2 Moderna (MRNA) provided business updates for the first quarter of 2020 and highlighted pipeline progress. The current most important of the news is that the FDA has cleared Moderna’s coronavirus vaccine to proceed with the central Phase 2 study. The . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Moderna Therapeutics Virtual Vaccine Day On April 7, 2020 Moderna Therapeutics (MRNA) announced that it will host its virtual Vaccine Day for analysts and investors at 8:00 a.m. EST on Tuesday, April 14th. Moderna informed that during its first Vaccine Day Stéphane Bancel Chief Executive Officer and Tal Zaks Chief Medical Officer as well as key opinion . . . This content is for paid …
COVID-19 at Its Peak? The number of deaths from the COVID-19 outbreak in NYC are expected to peak soon. This expectation is coming from a prestigious trustworthy Washington University. The news also stated that Italy is turning the corner if it has not already turned it. They are reporting the lowest death toll for two weeks. France also reported a slowing of daily deaths while …
Vertex and Regeneron Will Survive the Coronavirus Market Vertex We picked Vertex (VRTX) on March 18, 2011 at $44.39. The stock closed at $218 at the end of 2019. It rallied in mid-February reaching $247.78 then the unexpected and unseen novel coronavirus started infecting the world. Our 2020 target is still $280. We decided upon this new target in . . . This content is …
COVID-19 and the Nation's Hospitals Disagreeable news with regard to the nation's hospitals is their unpreparedness to face a sudden crisis, let alone an unexpected and unprecedented pandemic. The system the hospitals are running on has been causing problems for a some time now, not just since the Coronavirus pandemic. Since the COVID-19 cases have been rushed to hospitals many unwarranted, unacceptable, intolerable and dangerous …
Exelixis, Takeda and Japanese RCC Patients Today we learned from Exelixis (EXEL) that Takeda Pharmaceutical Company Limited, which is responsible for the clinical development and commercialization of Exelixis' oncology drug CABOMETYX® (cabozantinib . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Compugen Soaring in an Extremely Down Market The stocks' prices tumbled today except for very few and one of them is Compugen (CGEN). This firm announced good news; we wish it has chosen a better day for its announcement. Compugen's stock managed to rally as investor's enthusiasm was unlimited; knowing, in fact, what the success of Compugen immuno . . . This content is for …
NanoViricides and COVID-19 NanoViricides (NNVC), a development-stage nano-biopharmaceutical company with a proprietary and patented drug development focused on viral diseases, is among the few firms that are actively working on developing products that can treat the coronavirus disease COVID-19 which is caused by SARS-CoV-2 virus, or 2019-nCoV, now known also known as the . . . This content is for paid subscribers. Please click here to …
Moderna Therapeutics Among all the firms announcing their interest in working towards designing and producing a preventive vaccine for COVID-19 only Moderna (MRNA) has accomplished that job and delivered it to the health authorities to decide upon the next step. Moderna’s stock soared. The stock did not go up in expectation of the millions . . . This content is for paid subscribers. Please click here …
Regeneron, Moderna, and COVID-19 The spread of COVID-19, minute creatures that seem to be trying to defeat us, has been accused of bringing the market down over 1000 points yesterday. Investors who love the biotech stocks they carefully and accurately hand-picked should take advantage of the temporary market drop to buy more of their preferred stocks at bargain prices. In so doing, the cost of …
Cassava Sciences From NEWSWIRE we learned that Cassava Sciences (SAVA), a clinical-stage biotechnology company focusing on Alzheimer’s disease, announced that The Journal of Prevention of Alzheimer’s Disease (JPAD), a peer-reviewed journal for the research community, has published results from the Company’s Phase 2a study; its drug PTI-125
Regeneron Pharmaceuticals Stock is Rallying Regeneron Pharmaceuticals (REGN) stock outperformed last week gaining over $27. The stock’s soaring was not the outcome of the market’s outperformance, for several consecutive days, but because the . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
